Correction: Kikuchi, K., et al., Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci. 2013, 14, 18899–18924
The original version of the paper [1] reports that "This ACTIVE I study was supported by Pfizer" (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer. [...]
Saved in:
Published in | International journal of molecular sciences Vol. 15; no. 4; pp. 5410 - 5411 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel
MDPI AG
27.03.2014
Molecular Diversity Preservation International (MDPI) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The original version of the paper [1] reports that "This ACTIVE I study was supported by Pfizer" (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer. [...] |
---|---|
Bibliography: | correction |
ISSN: | 1422-0067 1661-6596 1422-0067 |
DOI: | 10.3390/ijms15045410 |